A Phase I/II Trial of TG01 and Gemcitabine as adjuvant therapy for treating patients with pancreatic cancer

Registry ID

EUCTR2012-002400-40

Source registry

EUCTR

Status

Completed

Phase

PHASE2

Sponsor

Targovax AS

Start date

2012-11-09

Completion date

2019-05-10

Last update

2026-08-16

Conditions

• Adenocarcinoma of the Pancreas

Summary

To assess the potential for interference of Gemcitabine on immune response to TG01 as determined by TG01 specific DTH skin test reaction and T-cell function in peripheral blood in patients receiving TG01 and GM-CSF after primary resection of pancreatic adenocarcinoma

Locations

• , , UK
• , , Norway
• , , Spain

Related clinical trials

• The HistoSonics Edison™ System for Treatment of Pancreatic Adenocarcinoma Using Histotripsy
• Neoadjuvant mFOLFIRINOX With Perioperative Oral Hydroxychloroquine in Resectable Pancreatic Adenocarcinoma
• Valproic Acid/Simvastatin Plus Gemcitabine/Nab-paclitaxel Based Regimens in Untreated Metastatic Pancreatic Adenocarcinoma Patients
• Resection/Synchronous Pulmonary or Hepatic Oligometastatic Pancreatic Ductal Adenocarcinoma
• Efficacy and Safety of TPIAT for Resectable Adenocarcinoma of the Pancreas Region at High Risk of Postoperative Fistula
• Is the 3D-PANC MSP Model Superior to CT for Assessing Response to Neoadjuvant Treatment in PCA Patients?

View on source registry